O	0	4	Time
O	5	11	course
O	12	15	and
O	16	26	management
O	27	29	of
O	30	33	key
O	34	41	adverse
O	42	48	events
O	49	55	during
O	56	59	the
O	60	70	randomized
O	71	76	phase
O	77	80	III
O	81	86	SOLAR
O	86	87	-
O	87	88	1
O	89	94	study
O	95	97	of
B-intervention	98	102	PI3K
I-intervention	103	112	inhibitor
I-intervention	113	122	alpelisib
I-intervention	123	127	plus
I-intervention	128	139	fulvestrant
O	140	142	in
O	143	151	patients
O	152	156	with
O	157	159	HR
O	159	160	-
O	160	168	positive
O	169	177	advanced
O	178	184	breast
O	185	191	cancer
O	191	192	.

O	193	202	Alpelisib
O	203	204	(
O	204	205	α
O	205	206	-
O	206	215	selective
O	216	236	phosphatidylinositol
O	237	238	3
O	238	239	-
O	239	245	kinase
O	246	255	inhibitor
O	255	256	)
O	257	261	plus
O	262	273	fulvestrant
O	274	276	is
O	277	285	approved
O	286	288	in
O	289	297	multiple
O	298	307	countries
O	308	311	for
O	312	315	men
O	316	319	and
O	320	334	postmenopausal
O	335	340	women
O	341	345	with
O	346	352	PIK3CA
O	352	353	-
O	353	360	mutated
O	360	361	,
O	362	369	hormone
O	370	378	receptor
O	378	379	-
O	379	387	positive
O	387	388	,
O	389	394	human
O	395	404	epidermal
O	405	411	growth
O	412	418	factor
O	419	427	receptor
O	428	429	2
O	429	430	-
O	430	438	negative
O	439	447	advanced
O	448	454	breast
O	455	461	cancer
O	462	471	following
O	472	483	progression
O	484	486	on
O	487	489	or
O	490	495	after
O	496	505	endocrine
O	506	513	therapy
O	513	514	.

O	515	516	A
O	517	525	detailed
O	526	539	understanding
O	540	542	of
O	543	552	alpelisib
O	552	553	'
O	553	554	s
O	555	561	safety
O	562	569	profile
O	570	576	should
O	577	583	inform
O	584	591	adverse
O	592	597	event
O	598	599	(
O	599	601	AE
O	601	602	)
O	603	613	management
O	614	617	and
O	618	625	enhance
O	626	633	patient
O	634	638	care
O	638	639	.

O	640	643	AEs
O	644	646	in
O	647	650	the
O	651	656	phase
O	657	660	III
O	661	666	SOLAR
O	666	667	-
O	667	668	1
O	669	674	trial
O	675	679	were
O	680	688	assessed
O	689	691	in
O	692	700	patients
O	701	705	with
O	706	709	and
O	710	717	without
O	718	724	PIK3CA
O	725	734	mutations
O	734	735	.

O	736	739	The
O	740	746	impact
O	747	749	of
O	750	758	protocol
O	758	759	-
O	759	768	specified
O	769	771	AE
O	771	772	-
O	772	782	management
O	783	798	recommendations
O	799	802	was
O	803	812	evaluated
O	812	813	,
O	814	823	including
O	824	826	an
O	827	836	amendment
O	837	839	to
O	840	848	optimize
O	849	862	hyperglycemia
O	863	866	and
O	867	871	rash
O	872	882	management
O	882	883	.

O	884	892	Patients
O	893	897	were
O	898	906	randomly
O	907	915	assigned
O	916	918	to
O	919	926	receive
O	927	938	fulvestrant
O	939	943	plus
O	944	953	alpelisib
O	954	955	(
O	955	956	n
O	957	958	=
B-intervention-participants	959	962	284
O	962	963	)
O	964	966	or
B-control	967	974	placebo
O	975	976	(
O	976	977	n
O	978	979	=
B-control-participants	980	983	287
O	983	984	)
O	984	985	.

O	986	989	The
O	990	994	most
O	995	1001	common
B-outcome	1002	1007	grade
I-outcome	1008	1009	3
I-outcome	1009	1010	/
I-outcome	1010	1011	4
I-outcome	1012	1015	AEs
O	1016	1020	with
O	1021	1030	alpelisib
O	1031	1035	were
B-outcome	1036	1049	hyperglycemia
O	1050	1051	(
B-outcome	1051	1056	grade
I-outcome	1057	1058	3
O	1058	1059	,
O	1060	1062	32
O	1062	1063	.
O	1063	1064	7
O	1064	1065	%
O	1065	1066	;
B-outcome	1067	1072	grade
I-outcome	1073	1074	4
O	1074	1075	,
O	1076	1077	3
O	1077	1078	.
O	1078	1079	9
O	1079	1080	%
O	1080	1081	)
O	1081	1082	,
B-outcome	1083	1087	rash
O	1088	1089	(
B-outcome	1089	1094	grade
I-outcome	1095	1096	3
O	1096	1097	,
O	1098	1099	9
O	1099	1100	.
O	1100	1101	9
O	1101	1102	%
O	1102	1103	)
O	1103	1104	,
O	1105	1108	and
B-outcome	1109	1117	diarrhea
O	1118	1119	(
B-outcome	1119	1124	grade
I-outcome	1125	1126	3
O	1126	1127	,
O	1128	1129	6
O	1129	1130	.
O	1130	1131	7
O	1131	1132	%
O	1132	1133	)
O	1133	1134	.

B-outcome	1135	1141	Median
I-outcome	1142	1146	time
I-outcome	1147	1149	to
I-outcome	1150	1155	onset
I-outcome	1156	1158	of
I-outcome	1159	1164	grade
I-outcome	1165	1166	≥
I-outcome	1166	1167	3
I-outcome	1168	1176	toxicity
O	1177	1180	was
O	1181	1183	15
O	1184	1188	days
O	1189	1190	(
O	1190	1203	hyperglycemia
O	1203	1204	,
O	1205	1210	based
O	1211	1213	on
O	1214	1221	fasting
O	1222	1228	plasma
O	1229	1236	glucose
O	1236	1237	)
O	1237	1238	,
O	1239	1241	13
O	1242	1246	days
O	1247	1248	(
B-outcome	1248	1252	rash
O	1252	1253	)
O	1253	1254	,
O	1255	1258	and
O	1259	1262	139
O	1263	1267	days
O	1268	1269	(
B-outcome	1269	1277	diarrhea
O	1277	1278	)
O	1278	1279	.

O	1280	1289	Metformin
O	1290	1295	alone
O	1296	1298	or
O	1299	1301	in
O	1302	1313	combination
O	1314	1318	with
O	1319	1324	other
O	1325	1337	antidiabetic
O	1338	1344	agents
O	1345	1348	was
O	1349	1353	used
O	1354	1356	by
O	1357	1361	most
O	1362	1370	patients
O	1371	1372	(
O	1372	1374	87
O	1374	1375	.
O	1375	1376	1
O	1376	1377	%
O	1377	1378	)
O	1379	1383	with
O	1384	1397	hyperglycemia
O	1397	1398	.

O	1399	1409	Preventive
O	1410	1414	anti
O	1414	1415	-
O	1415	1419	rash
O	1420	1430	medication
O	1431	1439	resulted
O	1440	1442	in
O	1443	1448	lower
B-outcome	1449	1458	incidence
O	1459	1460	(
B-outcome	1460	1463	any
I-outcome	1464	1469	grade
O	1469	1470	,
B-iv-bin-percent	1471	1473	26
I-iv-bin-percent	1473	1474	.
I-iv-bin-percent	1474	1475	7
I-iv-bin-percent	1475	1476	%
O	1477	1483	versus
B-cv-bin-percent	1484	1486	64
I-cv-bin-percent	1486	1487	.
I-cv-bin-percent	1487	1488	1
I-cv-bin-percent	1488	1489	%
O	1489	1490	)
O	1491	1494	and
B-outcome	1495	1503	severity
I-outcome	1504	1506	of
I-outcome	1507	1511	rash
O	1512	1513	(
B-outcome	1513	1518	grade
I-outcome	1519	1520	3
O	1520	1521	,
B-iv-bin-percent	1522	1524	11
I-iv-bin-percent	1524	1525	.
I-iv-bin-percent	1525	1526	6
I-iv-bin-percent	1526	1527	%
O	1528	1534	versus
B-cv-bin-percent	1535	1537	22
I-cv-bin-percent	1537	1538	.
I-cv-bin-percent	1538	1539	7
I-cv-bin-percent	1539	1540	%
O	1540	1541	)
O	1542	1548	versus
O	1549	1551	no
O	1552	1564	preventative
O	1565	1575	medication
O	1575	1576	.

B-outcome	1577	1593	Discontinuations
I-outcome	1594	1597	due
I-outcome	1598	1600	to
I-outcome	1601	1606	grade
I-outcome	1607	1608	≥
I-outcome	1608	1609	3
I-outcome	1610	1613	AEs
O	1614	1618	were
O	1619	1624	lower
O	1625	1634	following
O	1635	1639	more
O	1639	1640	-
O	1640	1648	detailed
O	1649	1651	AE
O	1652	1662	management
O	1663	1673	guidelines
O	1674	1675	(
B-iv-bin-percent	1675	1676	7
I-iv-bin-percent	1676	1677	.
I-iv-bin-percent	1677	1678	9
I-iv-bin-percent	1678	1679	%
O	1680	1686	versus
B-cv-bin-percent	1687	1689	18
I-cv-bin-percent	1689	1690	.
I-cv-bin-percent	1690	1691	1
I-cv-bin-percent	1691	1692	%
O	1693	1703	previously
O	1703	1704	)
O	1704	1705	.

O	1706	1714	Patients
O	1715	1719	with
O	1720	1726	PIK3CA
O	1727	1736	mutations
O	1737	1740	had
O	1741	1742	a
O	1743	1749	median
O	1750	1759	alpelisib
O	1760	1764	dose
O	1765	1774	intensity
O	1775	1777	of
O	1778	1781	248
O	1782	1784	mg
O	1784	1785	/
O	1785	1788	day
O	1788	1789	.

B-outcome	1790	1796	Median
I-outcome	1797	1808	progression
I-outcome	1808	1809	-
I-outcome	1809	1813	free
I-outcome	1814	1822	survival
O	1823	1827	with
O	1828	1837	alpelisib
O	1838	1841	was
B-iv-cont-median	1842	1844	12
I-iv-cont-median	1844	1845	.
I-iv-cont-median	1845	1846	5
O	1847	1850	and
B-iv-cont-median	1851	1852	9
I-iv-cont-median	1852	1853	.
I-iv-cont-median	1853	1854	6
I-iv-cont-median	1855	1861	months
O	1862	1865	for
O	1866	1875	alpelisib
O	1876	1880	dose
O	1881	1892	intensities
O	1893	1895	of
O	1896	1897	≥
O	1897	1900	248
O	1901	1903	mg
O	1903	1904	/
O	1904	1907	day
O	1908	1911	and
O	1912	1913	<
O	1913	1916	248
O	1917	1919	mg
O	1919	1920	/
O	1920	1923	day
O	1923	1924	,
O	1925	1937	respectively
O	1937	1938	,
O	1939	1947	compared
O	1948	1952	with
B-cv-cont-median	1953	1954	5
I-cv-cont-median	1954	1955	.
I-cv-cont-median	1955	1956	8
I-cv-cont-median	1957	1963	months
O	1964	1968	with
O	1969	1976	placebo
O	1976	1977	.

B-outcome	1978	1991	Hyperglycemia
I-outcome	1992	1995	and
I-outcome	1996	2000	rash
O	2001	2009	occurred
O	2010	2015	early
O	2016	2022	during
O	2023	2032	alpelisib
O	2033	2042	treatment
O	2042	2043	,
O	2044	2049	while
O	2050	2058	diarrhea
O	2059	2067	occurred
O	2068	2070	at
O	2071	2072	a
O	2073	2078	later
O	2079	2083	time
O	2084	2089	point
O	2089	2090	.

O	2091	2096	Early
O	2097	2111	identification
O	2111	2112	,
O	2113	2123	prevention
O	2123	2124	,
O	2125	2128	and
O	2129	2141	intervention
O	2141	2142	,
O	2143	2152	including
O	2153	2164	concomitant
O	2165	2176	medications
O	2177	2180	and
O	2181	2190	alpelisib
O	2191	2195	dose
O	2196	2209	modifications
O	2209	2210	,
O	2211	2219	resulted
O	2220	2222	in
O	2223	2227	less
B-outcome	2228	2234	severe
I-outcome	2235	2245	toxicities
O	2245	2246	.

O	2247	2257	Reductions
O	2258	2260	in
O	2261	2270	treatment
O	2271	2287	discontinuations
O	2288	2291	and
O	2292	2300	improved
O	2301	2312	progression
O	2312	2313	-
O	2313	2317	free
O	2318	2326	survival
O	2327	2329	at
O	2330	2336	higher
O	2337	2346	alpelisib
O	2347	2351	dose
O	2352	2363	intensities
O	2364	2371	support
O	2372	2375	the
O	2376	2380	need
O	2381	2384	for
O	2385	2392	optimal
O	2393	2395	AE
O	2396	2406	management
O	2406	2407	.

O	2408	2422	CLINICALTRIALS
O	2422	2423	.

O	2424	2435	NCT02437318
O	2435	2436	.
